MediWound Ltd. reported fourth-quarter 2025 revenue of $48.2 million, surpassing estimates, with non-GAAP EPS of $0.42. Growth was fueled by increased U.S. and European sales of its advanced wound care products, reinforcing the company’s market position in specialty medical devices.
- Q4 2025 revenue reached $48.2 million, surpassing the $46.1 million consensus
- Non-GAAP EPS of $0.42 exceeded the $0.37 expected
- U.S. sales of MWW-120 and MWW-130 grew 31% and 27% YoY
- European sales increased 19% with expanded distribution in key markets
- International revenue accounted for 62% of total Q4 sales
- Company reaffirmed 2026 revenue guidance of $195M–$205M
MediWound Ltd. delivered a standout performance in Q4 2025, reporting revenue of $48.2 million, a 23% year-over-year increase and above the consensus forecast of $46.1 million. The company achieved non-GAAP earnings per share of $0.42, exceeding the expected $0.37, driven by strong commercial execution across key markets. The growth was primarily attributable to expanded adoption of MediWound’s proprietary wound care therapies, including its MWW-120 and MWW-130 product lines, which saw 31% and 27% year-over-year sales increases in the United States, respectively. European markets contributed significantly as well, with sales rising by 19% on expanded distribution in Germany, France, and the UK. The company’s strategic focus on hospital-based specialty wound care, combined with ongoing reimbursement improvements in key jurisdictions, has strengthened its revenue visibility. Total international revenue accounted for 62% of Q4 2025 sales, highlighting the global traction of its product portfolio. The results have bolstered investor confidence, with shares of MWW rising 7.3% in after-hours trading. The positive momentum also positively impacted related biotech stocks, including LQDT and DXCM, which saw modest gains reflecting broader sector optimism. Management reiterated its full-year 2026 guidance, projecting revenue between $195 million and $205 million.